What were the key takeaways from Cibus’s earnings call?

What guidance did Cibus's management provide for the next earnings period?

What is the market's earnings forecast for Cibus next quarter?

What is Cibus's latest dividend and current dividend yield?

What does Cibus do and what are its main business segments?

What factors drove the changes in Cibus's revenue and profit?

What were the key takeaways from Cibus's earnings call?

What is Cibus's gross profit margin?

- **$200M+ Rice Royalty Potential**: 7 partnerships across Americas and India drive long-term revenue growth.
- **EU Regulatory Breakthrough**: 100M acres of new opportunity for gene-edited crops in Europe.
- **12-15 Month Gene Editing Timeline**: Enables rapid integration into seed companies' breeding programs.
- **First Fragrance Payment**: Sustainable ingredients program demonstrates commercial viability, targeting $20M-$40M annual royalties.
- **Financial Stability**: $22.3M capital raise and $10M cost savings extend cash runway to late 2026.

**【Management Opening Remarks】**
- CFO Carlo Broos welcomed participants, reminded of forward-looking statements, and noted the availability of the webcast and press release.

**【CEO Commentary】**
- **Landmark Year Achievements**: 2025 saw advancements in gene editing technology, commercialization, and regulatory progress, including EU's new genomic techniques legislation.
- **Rice Program Momentum**: 7 rice customers across the Americas represent $200M+ annual royalty potential. Key partnerships include Interoc (Latin America), Semillano (Colombia), and AgVaya (India), with initial commercial launches targeted for 2027-2030.
- **Gene Editing Efficiency**: Cibus can deliver edited elite genetics to customers within 12-15 months, enabling integration into seed companies' breeding programs.
- **Sustainable Ingredients Breakthrough**: Received first payment from biofragrance program, with commercial scale production expected later in 2026.
- **Regulatory Wins**: EU political agreement on genomic techniques, U.K. PBO framework, and U.S. APHIS approvals support global expansion.

**【CFO Financial Commentary】**
- **Cash Position**: $9.9M as of Q4 2025, with $22.3M raised in January 2026, extending cash runway to late Q3 2026.
- **Cost Savings**: Full-year 2025 operating expenses reduced by $10M (R&D: $3M, SG&A: $1.7M), supporting $30M+ annual cash usage target.
- **Financial Performance**: Net loss of $31.9M for Q4 2025, driven by royalty liability interest and reduced revenue recognition.

**【Q&A Highlights】**
- **EU Regulatory Impact**: 100M acres of opportunity in Europe, with interest from major seed companies in Winter Oilseed Rape traits.
- **Latin America Commercialization**: Interoc partnership progressing toward 2027 launch, with field trials and chemical registrations underway.
- **Gene Editing Scale**: Streamlined workflows and AI integration enable multiple crop trait development without significant R&D expansion.
- **Fragrance Expansion**: Targeting $20M-$40M annual royalties, with potential to expand beyond initial partnership.
- **Financing Flexibility**: Focus on near-term rice and fragrance revenue, with no immediate need for additional funding beyond current runway.

Cibus, Inc.(CBUS)-20260318-2025 Q4 Earnings call transcript

- **Rice Trait Milestone**: 7 customer agreements across 3 continents, $200M+ annual royalty potential from herbicide-tolerant rice.
- **Biofragrance Breakthrough**: Pre-commercial scale-up complete, first R&D offset payments received in Q4 2025.
- **Cost Efficiency**: $5M YoY operating expense reduction, annual cash burn target of $30M by 2026.
- **Regulatory Momentum**: EU gene editing legislation nearing completion; India completes first gene-edited rice trials.
- **HT2 Trait Expansion**: Canola herbicide tolerance trait shows strong field results, multi-crop development underway.

**【CEO Summary Section】**
- Signed 7 Rice customer agreements across USA, Latin America, and India, representing 5-7 million addressable acres and $200M+ annual royalty potential.
- Launched HT1/HT3 herbicide-tolerant rice traits in Latin America (2027) and U.S. (2028), with India targeted for 2030.
- Completed pre-commercial biofragrance scale-up, receiving first R&D offset payments in Q4 2025.
- Streamlined operations reduced annual net cash usage to $30M by 2026, extending runway to Q2 2026.
- Expanded Board with Kimberly Box (HP exec) and Craig Wichner (sustainable ag expert) to support commercialization.

**【CFO Financial Commentary】**
- Q3 2025 cash balance: $23.9M, sufficient for operations into early Q2 2026.
- Operating expenses reduced by $5M YoY (Q3 2025 vs Q3 2024): 
  - R&D: $10.8M (-$2.2M)
  - SG&A: $5.2M (-$2.5M)
- Net loss narrowed to $24.3M (vs $201.5M YoY), driven by $181M goodwill impairment in Q3 2024.
- Consolidated Oberlin facility and reduced workforce to achieve $30M annual cash burn target.

**【Q&A Highlights】**
- **Regulatory Progress**: EU new breeding technologies legislation nearing finalization; India completed first gene-edited rice field trials.
- **HT2 Trait Expansion**: Canola herbicide tolerance trait showing strong field results, seeking seed company partnerships for multi-crop development.
- **Biofragrance Ramp-Up**: 2026 revenue expected in single-digit millions, targeting $20-40M long-term in $65B fragrance market.
- **India Strategy**: Collaborating with AgVaya to access 120M acres of rice, targeting 2030 commercial launch.
- **Capital Allocation**: Exploring all financing options to support 2026 commercialization, prioritizing non-dilutive solutions.

Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript

- **Rice Traits on Track for $200M Royalty Revenue:** Latin America launches in 2027, U.S. in 2028, with 5 customers signed.
- **Biofragrances to Generate $M in 2026:** Scale-up complete, nominal 2025 revenue, full commercialization in 2026.
- **Cost Discipline Extends Runway:** $30M annual net cash usage by 2026, $36.5M cash as of Q2.
- **Gene Editing Regulatory Momentum:** EU resolution expected in 6 months, enabling global trait commercialization.
- **Soybean Platform Breakthrough:** 125M-acre opportunity with $10-15/acre royalty potential.


**【Interim CFO Opening Remarks】**
- Provided regulatory and financial updates, emphasizing the company's focus on near-term revenue drivers and capital discipline.
- Highlighted the importance of maintaining a runway through 2026 while positioning for commercialization.

**【Interim CEO, Peter Beetham - Strategic Update】**
- **Rice Herbicide Tolerance Traits (HT1/HT3):** 
  - Potential annual royalty revenue of $200M across U.S. and Latin America.
  - On track for Latin America launches in 2027 and U.S. in 2028.
  - Signed 5th customer in Latin America, with field trials progressing as planned.
  - Delivered HT3 traits to a U.S. partner, enabling customer-led field trials.
- **Biofragrances Program:** 
  - Nominal revenues expected in late 2025, scaling to $M in 2026.
  - Completed first-stage scale-up of 2 products, meeting milestones.
- **Capital Allocation:** 
  - Streamlined operations to reduce annual net cash usage to ~$30M by 2026.
  - Focused on rice and biofragrances as highest-priority programs.

**【Chief Scientific Officer, Greg Gocal - Pipeline Update】**
- **Canola Programs:** 
  - HT2 field trials show promising results; Sclerotinia resistance program attracts partner interest.
- **Soybean Platform:** 
  - Demonstrated proof of concept for HT2 trait, targeting 125M acres with $10-15/acre royalty potential.
- **Alfalfa Program:** 
  - FDA-cleared altered lignin trait commercialized in 2025, offering higher-value alfalfa for livestock.
- **Regulatory Progress:** 
  - USDA AFIS designations of multiple traits as not regulated; positive EU trialogue momentum expected to resolve within 6 months.

**【Interim CFO, Cornelis Broos - Financial Update】**
- **Q2 2025 Financials:** 
  - Revenue: $933K (vs. $838K YoY), driven by partner-funded programs.
  - Net Loss: $26.6M (vs. $28.5M YoY), with cost-saving initiatives reducing R&D and SG&A expenses.
  - Cash: $36.5M as of Q2, with $27.5M raised in June public offering.
- **2026 Outlook:** 
  - Annual net cash usage reduced to ~$30M through workforce reduction and operational streamlining.
  - One-time severance charges of ~$0.5M in Q3.

**【Q&A Highlights】**
- **EU Regulatory Timeline:** 
  - Expected resolution of gene editing legislation within 6 months, enabling U.K.-style commercialization by late 2027.
- **Biofragrance Revenue Model:** 
  - 2025: Nominal revenue from scale-up material; 2026+: Royalty-based commercial sales.
- **Cash Burn Reduction:** 
  - Q2 2025: $26.6M net loss; 2026: ~$30M annual net cash usage.
- **Sustainable Ingredients Expansion:** 
  - Long-term opportunities in bio-based products (e.g., nonallergenic crops), but 2026 focus on rice and biofragrances.


Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript

- **Rice Platform Momentum**: 40% market share secured in North/Latin America, with 2027 commercial launch for stacked herbicide tolerance traits. 
- **Canola Disease Resistance Breakthrough**: 3rd mode of action Sclerotinia resistance shows promise, with field trials for modes 3/4 and stacked traits in 2025. 
- **Soybean Platform Progress**: Successful HT2 cell edits, positioning for 125M-acre market with $10-$15/acre royalties. 
- **Sustainable Ingredients Scaling**: 2025 nominal revenues, 2026-2028 ramp-up for biofragrance products, with minimal Cibus working capital needs. 
- **Regulatory Wins**: USDA non-regulation designation, Ecuador approval for HT rice, and EU regulatory modernization advancing. 
- **Financial Discipline**: $4M/month cash burn, $23.6M cash on hand, and focus on cost optimization and partner-funded growth. 


**【CEO Summary Section】**
- **Rice Platform Expansion**: Secured agreements with 4 major seed companies, representing ~40% of accessible rice acres in North and Latin America. Field trials for stacked herbicide tolerance traits in rice achieved a milestone, with commercial launch anticipated in 2027. 
- **Canola Disease Resistance**: Announced positive greenhouse data for a third mode of action for Sclerotinia resistance, with field trials for modes 3 and 4 planned for 2025. Stacked disease resistance traits are being tested in controlled environments. 
- **Soybean Platform Progress**: Achieved successful cell edits for HT2 trait in January, with plant edits expected later this year. Soybean platform development could access 125M acres with potential royalties of $10-$15/acre. 
- **Sustainable Ingredients Growth**: Completed first-stage scale-up for 2 biofragrance products, with nominal revenues expected in 2025 and ramp-up in 2026-2028. 
- **Regulatory Milestones**: USDA-APHIS designated 2 disease resistance traits as not regulated, Ecuador approved HT1/HT3 rice traits as equivalent to conventional breeding, and EU regulatory modernization efforts advancing. 

**【CFO Financial Commentary】**
- **Cash Position**: $23.6M as of Q1 2025, with $21.4M from January registered direct offering. Current cash sufficient to fund operations into Q3 2025. 
- **Revenue Growth**: $1M (Q1 2025) vs. $0.5M (Q1 2024), driven by partner-funded projects. 
- **Cost Optimization**: R&D expenses down 2% YoY to $11.8M, SG&A up 41% YoY to $9.9M due to $3M litigation accrual. Net loss narrowed to $28.4M (excluding $21M goodwill impairment). 
- **Burn Rate**: ~$4.4M/month post-cost-cutting initiatives, with focus on reducing further in 2025-2026. 

**【Q&A Key Takeaways】**
- **Regulatory Outlook**: EU trilogue discussions expected to finalize NGT legislation within 6 months, enabling secondary regulations for commercialization. U.K. trials for European-adapted crops underway. 
- **Sustainable Ingredients Scaling**: Fermentation-based products require minimal Cibus working capital, with inventory built by partners. Multiple pipeline molecules beyond initial 2 fragrances. 
- **Rice Commercialization**: Ecuador determination clears path for registration and commercialization, with first trait deliveries to Latin American customers by year-end. 
- **Cash Management**: $4M/month burn rate projected for 2025, with focus on optimizing partner-funded programs to reduce reliance on cash reserves. 
- **Soybean Platform Risk**: Complex trait development (e.g., white mold resistance) requires ongoing R&D investment, but early cell edits validate technical feasibility. 


Cibus (CBUS)-8 May 25-2025 Q1 Earnings call transcript

- **Gene Editing Breakthrough**: Cibus' RTDS platform enables indistinguishable-from-nature traits, bypassing GMO regulations and unlocking $300B global ag market.
- **Rice Trait Momentum**: 40% of North/Latin American rice acres under license for HT3; field trials show stacked herbicide tolerance success.
- **Canola Leadership**: 10 customers for disease-resistant traits; 2025 field trials for Sclerotinia resistance in North America.
- **Soybean Expansion**: Targeting 125M acres with HT2 and white mold resistance; soybean platform development on track.
- **Regulatory Win**: EU NGT legislation nearing adoption, opening European market for gene-edited crops.
- **Financial Strength**: $14.4M cash + $21.6M Q1 2025 raise; 20% cost reduction; no funding needs until Q3 2025.

**【Interim CEO Peter Beetham Opening Remarks】**
- Cibus is transitioning from a trait development company to a commercial trait company, with a focus on gene-edited traits that bypass GMO regulatory hurdles.
- Key achievements:
  - 40% of North and Latin American rice acres under agreements for HT3 herbicide tolerance traits.
  - Field trials for stacked herbicide tolerance in rice show breakthrough results.
  - 10 customers for canola traits, including 6 progressing PSR (Pod Shatter Reduction) for 7M acres.
  - Soybean platform development progressing, targeting 125M acres with HT2 and white mold resistance.
- Regulatory progress: EU NGT legislation nearing final adoption, treating gene-edited crops like conventional breeding.
- New collaborations: AI partnership with Biographica for disease resistance gene discovery.

**【Interim CFO Carlo Broos Financial Update】**
- Cash balance: $14.4M as of Q4 2024, with $21.6M raised in Q1 2025, sufficient to fund operations into late Q3 2025.
- R&D expenses: $12.4M (Q4 2024) vs $14.2M (Q4 2023), down 12% due to cost-cutting.
- Net loss: $25.8M (Q4 2024) vs $277.2M (Q4 2023), excluding $249M goodwill impairment.
- Operating expenses reduced by 20% through strategic realignment.

**【Q&A Highlights】**
1. **EU Regulatory Impact**: 
   - Final NGT legislation expected to open European market for gene-edited crops.
   - 5 European customers already engaged on canola traits.
2. **Commercialization Timelines**:
   - Rice HT3: Field trials in US, Brazil, Colombia; commercial launch in key markets by 2026.
   - Canola PSR: UK field trials in 2025, potential 2026 royalties.
   - Soybean: Platform development on track, first trait data in 2025.
3. **Sustainability Progress**:
   - Biofragrance product expected to generate nominal revenue in 2025, scaling in 2026.
   - CPG partner-funded sustainable ingredient project advancing.
4. **Financial Sustainability**:
   - Current cash position supports all R&D activities through Q3 2025.
   - No need for additional funding beyond existing plans.


Actual										-17	-16.5	-14	-16.5	-12	-10.5	-10	-9	-7	-2.5	-6.5	-3	-5.45	-3.05	-1.59	-12.59	-1.12	-1.14	-7.63	-0.87	-1.34	-0.61	-0.44	-0.59
Forecast										-16	-14.1429	-14	-12.4	-12.6667	-9.5	-9.3333	-13.125	-8.75	-6.8333	-7	-5.5	-3	-0.3	-1.17	-1.43	-1.01	-0.8133	-0.8733	-0.6767	-0.5833	-0.6025	-0.4375	-0.3525
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.25%	-16.67%	0.00%	-33.06%	+5.26%	-10.53%	-7.14%	+31.43%	+20.00%	+63.41%	+7.14%	+45.45%	-81.67%	-916.67%	-35.90%	-780.42%	-10.89%	-40.17%	-773.70%	-28.57%	-129.73%	-1.24%	-0.57%	-67.38%

CBUS

CBUS fundamentals

CBUS Q4 2025 Earnings

Earnings Call

You can ask Aime

CBUS

CBUS fundamentals

CBUS Q4 2025 Earnings

Earnings Call

CBUS Earnings Call Summary for Q4/20254:30 PM on Mar 17, 2026

CBUS Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

CBUS Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

CBUS Earnings Call Summary for Q1/2025Invalid Date on May 8, 2025

CBUS Earnings Call Summary for Q4/20244:30 PM on Mar 20, 2025

You can ask Aime